# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...
Jefferies analyst Peter Welford downgrades Novartis (NYSE:NVS) from Buy to Hold.
Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate AS...
Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemi...
Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-s...
Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropat...
- Reuters